What The Study Did: In this open-label randomized clinical trial of high-risk patients with COVID-19 in Malaysia, a 5-day course of oral ivermectin administered during the first week of illness didn't reduce the risk of developing severe disease compared with standard care alone.
Authors: Steven Chee Loon Lim, M.R.C.P., of the Raja Permaisuri Bainun Hospital in Perak, Malaysia, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamainternmed.2022.0189)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2022.0189?guestAccessKey=58760460-df0f-4790-9257-8f3682dca39b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=021822
JAMA Internal Medicine